Clover Biopharmaceuticals (02197) Announces Monthly Return for October 2025

Bulletin Express11-05

During October 2025, Clover Biopharmaceuticals (02197) did not alter its authorized share capital, which remains at 2,000,000,000 ordinary shares with a par value of USD 0.0001 each, totaling USD 200,000.

As of the end of October 2025, the total issued shares increased by 386,000 to 1,297,780,179. This change primarily reflects the exercise of share options under the Pre-IPO Share Option Plan and the Post-IPO Share Option Plan. A total of 28,000 new shares were issued through the Pre-IPO Share Option Plan, while 358,000 new shares were issued under the Post-IPO Share Option Plan. The exercise of these options generated HKD 3,088 in total proceeds.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134111883?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 17:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134111883","market":"hk","top_or_hot":-1,"title":"Clover Biopharmaceuticals (02197) Announces Monthly Return for October 2025","media":"Bulletin Express","content":"<p>During October 2025, Clover Biopharmaceuticals (02197) did not alter its authorized share capital, which remains at 2,000,000,000 ordinary shares with a par value of USD 0.0001 each, totaling USD 200,000.</p>\n<p>As of the end of October 2025, the total issued shares increased by 386,000 to 1,297,780,179. This change primarily reflects the exercise of share options under the Pre-IPO Share Option Plan and the Post-IPO Share Option Plan. A total of 28,000 new shares were issued through the Pre-IPO Share Option Plan, while 358,000 new shares were issued under the Post-IPO Share Option Plan. The exercise of these options generated HKD 3,088 in total proceeds.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Biopharmaceuticals (02197) Announces Monthly Return for October 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Biopharmaceuticals (02197) Announces Monthly Return for October 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-05 17:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>During October 2025, Clover Biopharmaceuticals (02197) did not alter its authorized share capital, which remains at 2,000,000,000 ordinary shares with a par value of USD 0.0001 each, totaling USD 200,000.</p>\n<p>As of the end of October 2025, the total issued shares increased by 386,000 to 1,297,780,179. This change primarily reflects the exercise of share options under the Pre-IPO Share Option Plan and the Post-IPO Share Option Plan. A total of 28,000 new shares were issued through the Pre-IPO Share Option Plan, while 358,000 new shares were issued under the Post-IPO Share Option Plan. The exercise of these options generated HKD 3,088 in total proceeds.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02197","symbol_name":"三叶草生物-B","start_time":0,"source_url":"","article_id":"1134111883","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134111883","pubTimestamp":1762335949,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"During October 2025, Clover Biopharmaceuticals (02197) did not alter its authorized share capital, which remains at 2,000,000,000 ordinary shares with a par value of USD 0.0001 each, totaling USD...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02197":"三叶草生物-B"},"translate_title":"三叶草生物制药(02197)公布2025年10月份月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02197":1},"content_text":"During October 2025, Clover Biopharmaceuticals (02197) did not alter its authorized share capital, which remains at 2,000,000,000 ordinary shares with a par value of USD 0.0001 each, totaling USD 200,000.\nAs of the end of October 2025, the total issued shares increased by 386,000 to 1,297,780,179. This change primarily reflects the exercise of share options under the Pre-IPO Share Option Plan and the Post-IPO Share Option Plan. A total of 28,000 new shares were issued through the Pre-IPO Share Option Plan, while 358,000 new shares were issued under the Post-IPO Share Option Plan. The exercise of these options generated HKD 3,088 in total proceeds.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134111883","isCrawlerRequest":true}